A detailed history of Bank Of America Corp transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 1,654,962 shares of MCRB stock, worth $1.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,654,962
Previous 2,362,449 29.95%
Holding current value
$1.24 Million
Previous $3.31 Million 61.48%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.75 - $1.56 $530,615 - $1.1 Million
-707,487 Reduced 29.95%
1,654,962 $1.27 Million
Q4 2023

Feb 14, 2024

BUY
$0.93 - $2.15 $1.09 Million - $2.51 Million
1,168,553 Added 97.88%
2,362,449 $3.31 Million
Q2 2023

Aug 14, 2023

BUY
$4.67 - $6.55 $3.67 Million - $5.15 Million
786,699 Added 193.2%
1,193,896 $5.72 Million
Q1 2023

May 12, 2023

BUY
$4.95 - $6.09 $232,610 - $286,181
46,992 Added 13.05%
407,197 $2.31 Million
Q4 2022

Feb 10, 2023

BUY
$5.09 - $9.05 $627,922 - $1.12 Million
123,364 Added 52.09%
360,205 $2.02 Million
Q3 2022

Nov 14, 2022

BUY
$3.5 - $7.2 $519,655 - $1.07 Million
148,473 Added 168.02%
236,841 $1.52 Million
Q2 2022

Aug 12, 2022

SELL
$2.7 - $7.62 $364,589 - $1.03 Million
-135,033 Reduced 60.44%
88,368 $303,000
Q1 2022

May 16, 2022

BUY
$6.3 - $8.84 $631,215 - $885,706
100,193 Added 81.32%
223,401 $1.59 Million
Q4 2021

Feb 08, 2022

SELL
$6.02 - $11.43 $753,204 - $1.43 Million
-125,117 Reduced 50.38%
123,208 $1.03 Million
Q3 2021

Nov 15, 2021

BUY
$5.46 - $22.6 $540,862 - $2.24 Million
99,059 Added 66.36%
248,325 $1.73 Million
Q2 2021

Sep 13, 2021

BUY
$18.46 - $24.36 $2.76 Million - $3.64 Million
149,266 New
149,266 $3.56 Million

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $93.1M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.